VIOLIN: Vaccine Investigation and Online Information Network

MPL
Vaxjo ID	327
Vaccine Adjuvant Name	MPL
Adjuvant VO ID	VO_0001250
Description	GRA2 is a recombinant dense granule antigen of Toxoplasma gondii. MPL is monophosphoryl lipid A, an adjuvant.
Stage of Development	Research
Host Species for Testing	Mouse
Components	We aimed to examine whether immunization of a distinct strain of rodent with recombinant dense granule antigens (GRA2) combined with monophosphorryl lipid A (MPL) adjuvant elicits protective immune response against T.
Preparation	The paper mentions "recombinant dense granule antigens (GRA2)" formulated in "MPL adjuvant", but detailed preparation steps are not provided.
Function	Three weeks after immunization with GRA2, mice showed strong IgG1 and IFN-γ responses and significantly fewer brain cysts than controls. However, four months later, despite strong antibodies, IFN-γ levels and cyst reduction were not significant. Engages TLR4 pathway to promote Th1 responses. [PMC10067403]
Related Vaccine(s)	Subunit vaccine C. posadasii Subunit PMP1 Protein Vaccine (Coccidioides spp.) L. infantum SMT Protein Vaccine (Leishmania infantum) M. tuberculosis HBHA Protein Vaccine (Mycobacterium tuberculosis) Nontypeable H. influenzae NucA Protein vaccine (Haemophilus influenzae) Porin and S-LPS Extracted from Virulent Brucella abortus 2308 (Brucella spp.) Recombinant vaccinia A27L, D8L, and B5R Proteins with adjuvant MPL-TDM (Variola virus) S. pneumoniae CbpA Protein Vaccine (Streptococcus pneumoniae) S. pneumoniae PhpA-79 Protein Vaccine (Streptococcus pneumoniae) Conjugate vaccine Ag85B and ESAT-6 fusion protein (Mycobacterium tuberculosis)
References	*Babaie et al., 2018:* Babaie J, Amiri S, Homayoun R, Azimi E, Mohabati R, Berizi M, Sadaie MR, Golkar M. Immunization of C57BL/6 Mice with GRA2 Combined with MPL Conferred Partial Immune Protection against Toxoplasma gondii. Iranian biomedical journal. 2018; 22(1); 22-32. [PubMed: 28646827].

MPL